{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:20:19Z","timestamp":1790266819319,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","award":["2016WLJH33"],"award-info":[{"award-number":["2016WLJH33"]}],"id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR201709190013"],"award-info":[{"award-number":["ZR201709190013"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology of Shandong Province","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}]},{"name":"Science and Technology of Shandong Province","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejmech.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T16:40:21Z","timestamp":1520354421000},"page":"282-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors"],"prefix":"10.1016","volume":"150","author":[{"given":"Chunlong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin'ge","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Inks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. James","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-6695","authenticated-orcid":false,"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.03.002_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2183\/pjab.93.019","article-title":"Chemical and structural biology of protein lysine deacetylases","volume":"93","author":"Yoshida","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.ejmech.2018.03.002_bib2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.03.002_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.03.002_bib4","first-page":"1","article-title":"Histone deacetylase inhibitors: updated studies in various epigenetc-related diseases","volume":"2","author":"Clemens Zwergel","year":"2016","journal-title":"J.\u00a0Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2018.03.002_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Alokta Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib6","doi-asserted-by":"crossref","first-page":"15254","DOI":"10.1074\/jbc.M908988199","article-title":"Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor","volume":"275","author":"Hu","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib7","doi-asserted-by":"crossref","first-page":"C288","DOI":"10.1152\/ajpcell.00102.2014","article-title":"Histone deacetylase 8 regulates cortactin deacetylation and contraction in smooth muscle tissues","volume":"307","author":"Li","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2018.03.002_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/onc.2012.81","article-title":"Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8","volume":"32","author":"Yan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.03.002_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","article-title":"HDAC8: a multifaceted target for therapeutic interventions","volume":"36","author":"Chakrabarti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.03.002_bib10","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acsmedchemlett.6b00239","article-title":"Development of a potent and selective HDAC8 inhibitor","volume":"7","author":"Ingham","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.002_bib12","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cmdc.201600528","article-title":"Potent and selective non-hydroxamate histone deacetylase 8 inhibitors","volume":"11","author":"Kleinschek","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.03.002_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bioorg.2014.08.005","article-title":"Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8","volume":"57","author":"Kulandaivelu","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib14","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/cmdc.200900309","article-title":"Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors","volume":"4","author":"Galletti","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.03.002_bib15","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1016\/j.bmcl.2007.02.064","article-title":"Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors","volume":"17","author":"Krennhrubec","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.002_bib16","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A\u00a0novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2018.03.002_bib17","doi-asserted-by":"crossref","first-page":"9562","DOI":"10.1021\/jm300837y","article-title":"Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries","volume":"55","author":"Suzuki","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cmdc.201300414","article-title":"Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors","volume":"9","author":"Suzuki","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2018.03.002_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acsmedchemlett.7b00126","article-title":"Design, synthesis, and biological evaluation of tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors","volume":"8","author":"Taha","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.002_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drudis.2015.01.004","article-title":"How the flexibility of human histone deacetylases influences ligand binding: an overview","volume":"20","author":"Deschamps","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.03.002_bib21","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.bmc.2010.03.080","article-title":"On the inhibition of histone deacetylase 8","volume":"18","author":"Estiu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.002_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/cbdd.12787","article-title":"PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors","volume":"88","author":"Li","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.03.002_bib23","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Kyle","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.03.002_bib24","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1021\/jm401877m","article-title":"Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1\/3 dual inhibitors with potent oral antitumor activity","volume":"57","author":"Li","year":"2014","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341830237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341830237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:43:11Z","timestamp":1565311391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341830237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"alternative-id":["S022352341830237X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.002","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}